1 min read
Add as a preferred source on GoogleFDA Accepts Aquestive Therapeutics’ Anaphylm Application for Review
Anaphylm is an epinephrine sublingual film intended for emergency treatment of severe allergic reactions.
Aquestive Therapeutics announced Thursday, Oct. 15, that the U.S. Food and Drug Administration (FDA) accepted its resubmitted application for Anaphylm for review.
Anaphylm is an epinephrine formulation delivered as a sublingual film. It is designed for emergency treatment of severe allergic reactions.
Riza Dagoc
Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.